Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia

References

• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951.
   PubMed Web of Science ®Google Scholar
• Granfeldt Ostgard LS, Medeiros BC, Sengelov H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. JCO. 2015;33(31):3641–3649.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481–3485.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–4187.
   PubMed Web of Science ®Google Scholar
• Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89(9):3323–3329.
   PubMed Web of Science ®Google Scholar
• Miesner M, Haferlach C, Bacher U, et al. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as ‘AML not otherwise specified’ (AML-NOS) or ‘AML with myelodysplasia-related changes’ (AML-MRC). Blood. 2010;116(15):2742–2751.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365.
   PubMed Web of Science ®Google Scholar
• Hulegardh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90(3):208–214.
   PubMed Web of Science ®Google Scholar
• Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981;58(6):1203–1212.
   PubMed Web of Science ®Google Scholar
• Yates JW, Wallace HJ Jr, Ellison RR, et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485–488.
   PubMedGoogle Scholar
• VYXEOS™ (daunorubicin and cytarabine injection), solution for intravenous use [package insert]. Palo Alto, CA; Jazz Pharmaceuticals, Inc.; 2019.
   Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Vyxeos daunorubicin/cytarabine [Internet] [cited 2019 Sep 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos.
   Google Scholar
• Feldman EJ, Lancet JE, Kolitz JE, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. JCO. 2011;29(8):979–985.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. JCO. 2018;36(26):2684–2692.
   PubMed Web of Science ®Google Scholar
• Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. JCO. 2000;18(20):3558–3585.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. JCO. 2003;21(24):4642–4649.
   PubMed Web of Science ®Google Scholar
• Chiche E, Bertoli S, Recher C, et al. Deep response after CPX-351 treatment in T-AML and MRC-AML: a report from a multucentric French cohort. 24th Congress of the European Hematology Association; 2019 June 13–16; Amsterdam, the Netherlands. Abstract PF263.
   Google Scholar
• Feldman EJ, Kolitz JE, Trang JM, et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res. 2012;36(10):1283–1289.
   PubMed Web of Science ®Google Scholar
• Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006;5(7):1854–1863.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Mayer LD. Improving combination cancer therapy: the CombiPlex development platform. Future Oncol. 2018;14(13):1317–1332.
   PubMed Web of Science ®Google Scholar
• Lin TL, Newell LF, Stuart RK, et al. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. Cancer Chemother Pharmacol. 2019;84(1):163–173.
   PubMed Web of Science ®Google Scholar
• Aw A, Sabloff M, Sheppard D, et al. Evaluation of an outpatient model for treatment of acute myeloid leukemia. J Hematol. 2016;5(1):1–7.
   Google Scholar
• Wetzstein GA, Lancet JE, Kallner JE, et al. Safety, feasibility, and cost-effectiveness with outpatient administration of high-dose cytarabine consolidation in acute myeloid leukemia. Blood. 2008;112(11):2405–2405.
   Web of Science ®Google Scholar
• Savoie ML, Nevil TJ, Song KW, et al. Shifting to outpatient management of acute myeloid leukemia: a prospective experience. Ann Oncol. 2006;17(5):763–768.
   PubMed Web of Science ®Google Scholar
• Matza LS, Deger K, Howell T, et al. Health state utilities associated with treatment options for acute myeloid leukaemia (AML). International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress; 2017 Nov 4–8; Glasgow, Scotland.
   Google Scholar